Vaccine News and Research

Latest Vaccine News and Research

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

In a major breakthrough that comes after decades of research and nearly half a billion treatments in humans, scientists have finally unlocked how a key anti-parasitic drug kills the worms brought on by the filarial diseases river blindness and elephantitis.

11 Nov 2010

Scientists identify new way to drive dendritic cells from blood monocytes

Dendritic cells, known to be the prime movers of the body's immune response, are still notoriously difficult to study in humans. Samples, which come primarily from bone marrow or lymphoid tissue, are simply too difficult to obtain. But new research at Rockefeller University has shown scientists a way to study "authentic" dendritic cells from mouse monocytes, which are abundant in the blood, a much more accessible source in humans.

11 Nov 2010

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

Generex Biotechnology Corporationannounced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. has been awarded two Therapeutic Discovery Project grants, totaling $488,958.50, by the United States Internal Revenue Service (IRS) and the Department of Health and Human Services (HHS) pursuant to the Patient Protection and Affordable Care Act of 2010.

10 Nov 2010

HPV vaccination rates falter

According to the latest research lesser numbers of teenage girls and young women are getting infected by the human papillomavirus vaccine (HPV) – a virus linked to cervical cancer. Research also shows that most who start the vaccination regimen against the virus fail to take all three doses.

10 Nov 2010

Bioniche Life Sciences announces first quarter fiscal 2011 results

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of its 2011 fiscal year (ended September 30, 2010).

10 Nov 2010

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Hemispherx Biopharma, Inc. announced today grant awards totaling $488,958 from the U.S. Department of Treasury in support of its Ampligen and Alferon development programs.

10 Nov 2010

EuroNanoMed funds 8 projects with €8 Million for transnational research projects in nanomedicine

EuroNanoMed, a European funding initiative under the ERA-Net scheme of the European Commission aimed at advancing transnational research in Nanomedicine, announced today the projects that will be funded following its 2nd joint transnational call for collaborative research projects. Eight projects, involving 46 partners from 10 countries will be funded with €8 Million provided by EuroNanoMed partners. The research projects were chosen from 33 applications involving 178 applicant groups from 19 EU member and associated states/regions.

10 Nov 2010

Women taking HPV vaccine need only two HPV screening tests for rest of their lives: Research

Women who have had the human papillomavirus vaccine could need only two HPV screening tests for the rest of their lives according to new calculations being presented at the NCRI Cancer Conference in Liverpool.

10 Nov 2010

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Idera Pharmaceuticals, Inc. today announced two presentations of preclinical data from its autoimmune and inflammatory disease program at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Atlanta, Georgia. One presentation is entitled "IMO-3100, a Toll-like Receptor (TLR) Antagonist, Suppresses TLR7- and TLR9-mediated Immune Responses in Non-human Primates" (#856).

10 Nov 2010

Regional workshop to discuss diarrheal disease solutions for Asia

Each year, diarrheal disease claims the lives of 1.3 million children under five worldwide and hospitalizes millions more. The vast majority of these deaths occur in developing countries of Asia and Africa, but fortunately, interventions exist that can greatly reduce deaths and save lives. To bring attention to the solutions available today for defeating diarrhea, the Vietnam Ministry of Health, the National Pediatric Hospital of Vietnam, and PATH are hosting a two-day regional workshop where they will present the evidence and lessons learned from initiatives currently underway.

10 Nov 2010

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

Acute respiratory infections (ARIs) - such as influenza, pneumonia and respiratory syncytial virus (RSV) - cause 4.25 million deaths each year often among young children in developing countries, according to the Acute Respiratory Infections Atlas, which was released on Tuesday by the World Lung Foundation, Reuters reports (11/9).

10 Nov 2010

Only one-third of young women complete HPV regimen

Despite strong evidence of its effectiveness, few of the young women who are eligible for the human papillomavirus (HPV) vaccine take it, according to research presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10.

10 Nov 2010

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

Nabi Biopharmaceuticals announced today that it has completed enrollment in the second Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational candidate vaccine being developed to treat nicotine addiction and prevent smoking relapse.

10 Nov 2010

S.A.N.E. Vax calls for federal approval of reliable HPV genotyping test in cervical cancer prevention programs

In a letter addressed to Dr. Harold E. Varmus, director of the NCI, and Dr. Margaret Hamburg, FDA commissioner, Ms. Norma Erickson, president of S.A.N.E. Vax, Inc., requested that these two federal agencies recommend a reliable human papillomavirus (HPV) genotyping test to support the national virology-based cervical cancer prevention program for patient care. Erickson stated: "The NCI knows reliable HPV genotyping is based on using a PCR system with short target sequencing."

9 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

ORVACS has launched a Phase II study designed to test the hypotheses that combination therapy with potent antiviral agents and immunomodulator can lead to a decrease in the HIV viral reservoirs and, ultimately, to eradication of the virus. The study is currently being conducted at clinical sites in France, Spain, Italy, and the United Kingdom.

9 Nov 2010

Africare announces $1.42M grant from ExxonMobil for battle against malaria in Africa

Africare President Darius Mans announced today new investments from ExxonMobil to extend their partnership in its fight against malaria. ExxonMobil, which has long been a supporter of Africare, will fund three key malaria prevention and intervention programs in Africa.

9 Nov 2010

SIMPONI injection improves inflammation, structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

9 Nov 2010

CMS to review cancer vaccine, analysis shows high Medicare drug spending not correlated with better care

The Centers for Medicare & Medicaid Services are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.

9 Nov 2010

Advaxis collaborates with UBC to develop live attenuated Listeria vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has entered into a structured collaboration with the laboratory of Dr. Tobias Kollmann at the University of British Columbia (UBC) to develop live attenuated Listeria vaccines for the treatment of infectious disease and for new dosage forms of Listeria vaccines.

9 Nov 2010

Vaccine News and Research

Latest Vaccine News and Research

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

Scientists identify new way to drive dendritic cells from blood monocytes

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

HPV vaccination rates falter

Bioniche Life Sciences announces first quarter fiscal 2011 results

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

EuroNanoMed funds 8 projects with €8 Million for transnational research projects in nanomedicine

Women taking HPV vaccine need only two HPV screening tests for rest of their lives: Research

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Regional workshop to discuss diarrheal disease solutions for Asia

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

Only one-third of young women complete HPV regimen

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

S.A.N.E. Vax calls for federal approval of reliable HPV genotyping test in cervical cancer prevention programs

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

Africare announces $1.42M grant from ExxonMobil for battle against malaria in Africa

SIMPONI injection improves inflammation, structural damage in RA patients

CMS to review cancer vaccine, analysis shows high Medicare drug spending not correlated with better care

Advaxis collaborates with UBC to develop live attenuated Listeria vaccines

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Vaccine News and Research

Latest Vaccine News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in